Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

406
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
406
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

344
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
344
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

305
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
305
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

539
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
539
Bipolar Disorder01:30

Bipolar Disorder

246
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
246
Drug Therapy01:28

Drug Therapy

136
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
136

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proposal for Circadian Rhythms and Their Behavioral Outputs as Biomarkers in <i>DSM-6</i>: Response to Cuthbert et al.

The American journal of psychiatry·2026
Same author

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Mu-Opioid Signaling Engagement as a Candidate Maintenance Mechanism for Prolonging Ketamine's Antisuicidal Effects.

The American journal of psychiatry·2026
Same author

Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Major depressive disorder is associated with reduced intrinsic connectivity between the bed nucleus of the stria terminalis and ventral striatum.

Journal of psychiatry & neuroscience : JPN·2026
Same author

Response to Crockford et al.: Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference-in-differences time series.

Addiction (Abingdon, England)·2026

Related Experiment Video

Updated: Nov 7, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.8K

Ketamine for Bipolar Depression: A Systematic Review.

Anees Bahji1, Carlos A Zarate2, Gustavo H Vazquez3

  • 1Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Substance Use, Vancouver, British Columbia, Canada; Research in Addiction Medicine Scholars [RAMS] Program, Boston University Medical Centre, Boston, MA, USA.

The International Journal of Neuropsychopharmacology
|April 30, 2021
PubMed
Summary

Intravenous racemic ketamine shows promise for treating bipolar depression, with 61% of patients responding. While generally well-tolerated, further research is needed for long-term effects.

Keywords:
Bipolar disorderdepressionketaminesystematic review

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

804
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.1K

Related Experiment Videos

Last Updated: Nov 7, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.8K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

804
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.1K

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience and Mental Health Research

Background:

  • Ketamine demonstrates therapeutic potential in unipolar major depressive disorder.
  • Efficacy of ketamine for bipolar depression remains less understood.
  • This study addresses the need to evaluate ketamine's effectiveness and safety in bipolar depression.

Purpose of the Study:

  • To systematically review and synthesize evidence on ketamine's efficacy for bipolar depression.
  • To assess the tolerability and adverse events associated with ketamine treatment in this population.

Main Methods:

  • Systematic review of experimental studies on ketamine for bipolar depression.
  • Searched major databases including PubMed, MEDLINE, Embase, PsycINFO, and Cochrane.
  • Synthesized data on efficacy (depression score improvement) and tolerability (adverse events, dissociation, dropouts).

Main Results:

  • Six studies with 135 participants were analyzed; all received add-on intravenous racemic ketamine (0.5 mg/kg) with mood stabilizers.
  • Overall response rate (≥50% reduction in depression severity) was 61% for ketamine versus 5% for placebo.
  • Ketamine was generally well-tolerated, with rare instances of manic symptoms and transient dissociative effects post-infusion.

Conclusions:

  • Preliminary evidence supports the use of intravenous racemic ketamine for adult bipolar depression.
  • Further research is warranted to explore long-term outcomes and alternative ketamine formulations.
  • Ketamine represents a potential novel treatment avenue for this challenging condition.